Delivery of therapeutics across the blood-brain barrier and into the brain has been the single greatest challenge to treating hundreds of common and rare neurological diseases, including brain cancers, neurodegenerative diseases and metabolic disorders.

At Bioasis, we undertake this challenge by focusing on a single goal: revolutionizing science by transporting therapeutic payloads across the blood-brain barrier and into the brain. Bioasis has developed and is commercializing our proprietary brain delivery technology, the xB3 platform, to make life-saving drugs brain-penetrant and deliver those therapies at a therapeutically relevant dose.

The Blood-Brain Barrier Company

Upon acquiring research developed at the University of British Columbia (UBC) in 2007, Mr. Rob Hutchison founded Bioasis Technologies, Inc. in Vancouver, Canada. Bioasis became a publicly traded company in 2008 and trades on the TSX Venture Exchange under the symbol “BTI” and on the OTCQB under the symbol “BIOAF.”

Building upon the UBC work, Bioasis researchers created technology called the Transcend platform, capable of transporting therapeutics across the blood-brain barrier. Bioasis scientists then spent the last decade collaborating on research with leading pharmaceutical companies and academic institutions to further develop the Transcend-peptide platform. The platform is based on a human transport protein, melanotransferrin, which is found circulating in low levels in the blood. Preclinical studies have demonstrated that our platform technologies are independent of the transferrin receptor in their transport mechanism.

The Transcend-peptide platform will now be referred to as the xB3 platform and is part of the Bioasis patented portfolio that is revolutionizing therapeutic brain-drug delivery. Preclinical studies have demonstrated that the xB3 platform can transport molecules of varying sizes and types including monoclonal antibodies, enzymes, small molecules, small-interfering RNA (siRNA) and other types of gene therapies into the brain through a process called receptor-mediated transcytosis.

Delivering Hope

Our focus is to deliver hope to over 1.25 billion patients worldwide who suffer from hundreds of previously untreatable diseases and disorders of the central nervous system.

We know what our scientific advances can mean for a single patient — a second chance.